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Abstract
Background: Most patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
in primary care are prescribed an antibiotic, which may not always be appropriate and may cause harm. C-reactive
protein (CRP) is an acute-phase biomarker that can be rapidly measured at the point of care and may predict benefit
from antibiotic treatment in AECOPD. It is not clear whether the addition of a CRP point-of-care test (POCT) to clinical
assessment leads to a reduction in antibiotic consumption without having a negative impact on COPD health status.
Methods/design: This is a multicentre, individually randomised controlled trial (RCT) aiming to include 650 participants
with a diagnosis of AECOPD in primary care. Participants will be randomised to be managed according to usual care
(control) or with the addition of a CRP POCT to guide antibiotic prescribing. Antibiotic consumption for AECOPD within
4 weeks post randomisation and COPD health status (total score) measured by the Clinical COPD Questionnaire (CCQ)
at 2 weeks post randomisation will be co-primary outcomes. Primary analysis (by intention-to-treat) will determine
differences in antibiotic consumption for superiority and COPD health status for non-inferiority. Secondary outcomes
include: COPD health status, CCQ domain scores, use of other COPD treatments (weeks 1, 2 and 4), EQ-5D utility scores
(weeks 1, 2 and 4 and month 6), disease-specific, health-related quality of life (HRQoL) at 6 months, all-cause antibiotic
consumption (antibiotic use for any condition) during first 4 weeks post randomisation, total antibiotic consumption
(number of days during first 4 weeks of antibiotic consumed for AECOPD/any reason), antibiotic prescribing at
the index consultation and during following 4 weeks, adverse effects over the first 4 weeks, incidence of pneumonia
(weeks 4 and 6 months), health care resource use and cost comparison over the 6 months following randomisation.
Prevalence and resistance profiles of bacteria will be assessed using throat and sputum samples collected at baseline
and 4-week follow-up. A health economic evaluation and qualitative process evaluation will be carried out.
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Discussion: If shown to be effective (i.e. leads to a reduction in antibiotic use with no worse COPD health status), the use
of the CRP POCT could lead to better outcomes for patients with AECOPD and help reduce selective pressures driving
the development of antimicrobial resistance. PACE will be one of the first studies to evaluate the cost-effectiveness of a
POCT biomarker to guide clinical decision-making in primary care on patient-reported outcomes, antibiotic prescribing
and antibiotic resistance for AECOPD.
Trial registration: ISRCTN registry, ID: ISRCTN24346473. Registered on 20 August 2014.
Keywords: Acute exacerbation, Chronic obstructive pulmonary disease, Primary care, Point-of-care test, C-reactive protein
(CRP), Near-patient testing, Rationalising antibiotic prescribing, Antibiotic resistance, Cost-effectiveness, Resistance
Background
Point-of-care tests (POCTs) for acute infections are being
promoted to reduce inappropriate prescribing, reduce
antimicrobial resistance and to improve patient-reported
outcomes [1–4]. While POCTs are frequently subjected to
evaluations of analytic performance, they have often been
introduced into routine care before determining their clin-
ical effectiveness via rigorous clinical trials and without
understanding cost-effectiveness using relevant health and
service delivery outcomes.
Better targeting of antibiotics in acute exacerbations of
chronic obstructive pulmonary disease (AECOPD) repre-
sents a major opportunity for antimicrobial stewardship
and improved patient care. Over 80% of all antibiotics are
prescribed in the community [5] with high prescribing of
broad-spectrum antibiotics a particular concern. AECOPD
accounts for over two million antibiotic prescriptions each
year in the UK [6]. Cohort studies of patients recruited in
secondary care (which may not be representative of pri-
mary care but is the best relevant data available) suggest
that most COPD patients in the UK will suffer between
2.5 and 3 AECOPD per year. Over 70% of patients pre-
senting with AECOPD in primary care are prescribed an
antibiotic, accounting for 4.6% of all antibacterial prescrip-
tions every year [7] . COPD patients are an important and
increasingly large group who are at risk of significant mor-
tality, morbidity and hospitalisation and, as such, are more
likely to be prescribed broad-spectrum antibiotics [8].
However, many AECOPD are triggered by non-bacterial
causes, such as viral infections and environmental factors
including common pollutants or weather. It has been esti-
mated that approximately 70% of AECOPD are triggered
by an infection and 30% are caused by environmental fac-
tors. Of the 70% that are triggered by an infection, poten-
tial pathogenic bacteria are only isolated in 20–58% of
clinical samples, while pathogenic respiratory viruses can
be detected in approximately 50% [9–11].
Current antibiotic prescribing recommendations for
general practitioners (GPs) are generally based on symp-
toms alone (Anthonisen criteria; [12, 13]). However,
these symptoms are subjective and have insufficient
diagnostic accuracy to predict which patients can safely
be managed without antibiotics. Both our placebo-
controlled trial of antibiotics for AECOPD in primary
care [14] and systematic reviews [15] suggest that many
patients with AECOPD in primary care do not benefit
from antibiotic treatment. Overuse of antibiotics drives
antimicrobial resistance [16] and is facilitated by the
unnecessary consumption of antibiotics for COPD. Anti-
microbial treatment in patients with COPD decreases
the infecting load but does not usually entirely eradi-
cate organisms in the airways, increasing the risk of
resistant bacteria in COPD patients [17]. Infections
with antibiotic-resistant Streptococcus. pneumoniae in
patients with COPD are associated with antibiotic ex-
posure [18, 19]. A meta-analysis of seven studies of
respiratory tract bacteria that included 2605 partici-
pants showed that the pooled odds ratio (OR) for re-
sistance was 2.4 (1.4 to 3.9) within 2 months of
antibiotic treatment, and 2.4 (1.3 to 4.5) within 12
months [5]. The unnecessary use of antibiotics for
AECOPD not only contributes to the increasingly pressing
public health threat of antibiotic resistance, it also poses a
risk for the individual, and may increase the risk of subse-
quent antibiotic-resistant exacerbations and hasten disease
progression. Indiscriminate use of antibiotics in patients
with COPD is particularly high risk because the respira-
tory tracts of those affected are frequently colonised with
potential pathogens [20]. Unnecessary antibiotics also in-
crease the risk of patient side effects, waste money, and
undermine self-care [21].
A Cochrane systematic review of the use of antibiotics
in the management of exacerbations of COPD included
16 trials (n = 2068 participants), and reported that there
was insufficient evidence of effectiveness to guide anti-
biotic prescribing decisions in primary care [15].
C-reactive protein (CRP) is an acute-phase protein
found in the blood. The serum level of CRP increases
rapidly during infections, particularly in severe bacterial
infections. A prospective evaluation of 36 biomarkers
found that CRP was the most selective biomarker to
confirm AECOPD, and in combination with Anthonisen
criteria produced an area under the curve (AUC) of 0.88
(95% confidence interval (CI) 0.82–0.93), indicating that
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it had good diagnostic accuracy [22]. High serum CRP is
correlated with sputum purulence and raised serum
leucocyte counts and serum CRP is higher in the pres-
ence of bacterial infection [23, 24]. CRP rises in patients
with AECOPD and is correlated with Anthonisen score
and the degree of airflow limitation in hospitalised pa-
tients [25, 26]. As CRP levels are especially raised in the
presence of bacterial infection the treatment effect of an-
tibiotics increase with higher values of CRP [27]. A CRP
value above 50 mg/L (mean CRP of 97 mg/L, 95% CI
49–145) in hospitalised patients with AECOPD is associ-
ated with pneumonia and such patients are likely to
benefit from antibiotics [26]. CRP measurement inde-
pendently distinguished between pneumonia and other
causes of exacerbations in another study of patients hos-
pitalised with asthma and COPD (cut-off value of 48
mg/L with sensitivity of 91% and specificity of 93%) [28].
In a randomised controlled trial we conducted in pa-
tients with AECOPD in primary care, we found no dif-
ference in clinical cure between antibiotics and placebo
in those with a CRP < 40 (risk ratio (RR) for clinical fail-
ure = 0.72 (95% CI 0.28–1.82) p = 0.484) [23].
In an as yet unpublished study we found that over 50%
of COPD patients experiencing an exacerbation had a
CRP < 8 mg/L [29]. Our recent placebo-controlled trial
of antibiotics for AECOPD in primary care found mar-
ginal benefit from antibiotic treatment in patients with
only one or two Anthonisen criteria. Using Anthonisen
criteria to predict benefit from antibiotic treatment pro-
duced an area under the curve (AUC) of 0.708 (95% CI
0.616–0.801). Adding CRP increased this to an AUC of
0.842 (95% CI 0.76–0.924). Based on these data we an-
ticipate that using a CRP test alongside clinical assess-
ment will make it possible to safely reduce the antibiotic
prescription rate for this condition to around 45%.
CRP POCTs are widely available and are already com-
monly used to help guide antibiotic prescribing deci-
sions, including for lower respiratory tract infections
(LRTIs) and AECOPD in primary care in a number of
European countries (mostly Scandinavian) [30]. In two
trials evaluating the use of a CRP POCT to help target
antibiotic treatment for LRTIs in primary care [31, 32],
antibiotics were prescribed to 68% and 48% in the usual
care groups, respectively, and to 39% and 33% of pa-
tients managed by clinicians using a CRP POCT (with
training). CRP POCT was cost-effective in reducing anti-
biotic prescribing for LRTIs when there are no tests, or
low willingness to pay for the tests [31, 33]. However,
the benefits of CRP POCT in conjunction with clinical
examination has not yet been evaluated for AECOPD in
primary care in a randomised controlled trial. Now that
better and more rapid CRP POCTs are available [34],
there is potential for this technology to be widely used
for a variety of acute infections in primary care to better
guide antibiotic prescribing and in doing so, help reduce
unnecessary antibiotic consumption and thus contain
antibiotic resistance. PACE seeks to establish whether a
CRP POCT can safely and cost-effectively be used to
better target antibiotic treatment for AECOPD in pri-
mary care to those that are most likely to benefit, so that
overall antibiotic use is decreased without compromising
COPD-related health status.
Methods/design
Objectives
The primary objective is to determine whether the addition
of a CRP POCT (with training on test use and advice on
interpretation) to usual care for managing AECOPD leads
to a reduction in antibiotic consumption for AECOPD
without negatively impacting on COPD health status, com-
pared with usual care alone. Table 1 lists the primary and
secondary objectives and outcome measures.
Trial design
PACE is a two-arm, open, individually randomised (1:1)
controlled trial involving general practitioners in general
medical practices that are part of primary care research
networks in the UK. Patients presenting with AECOPD
will be randomised to clinical management based on
usual care alone or usual care with the addition of a
CRP POCT. Training in POCT use and interpretation
will help to guide decisions about the use of antibiotic
treatment for AECOPD.
Our primary research question centres on whether CRP
POCT-informed management of patients with AECOPD
reduces antibiotic use without negatively impacting on
COPD health status. We will answer this question in
terms of co-primary outcome measures; antibiotic con-
sumption for AECOPD within 4 weeks post randomisa-
tion and COPD health status 2 weeks post randomisation.
Between-group differences in antibiotic consumption will
be investigated for superiority, while differences in COPD
health status will be investigated for non-inferiority.
Outcome measures
The co-primary outcome measure will comprise:
1. Antibiotic consumption at any point during the 4
weeks post randomisation for AECOPD, measured
using telephone interviews at 1 week and 2 weeks
and face-to-face interview at 4 weeks
2. COPD health status measured by the Clinical COPD
Questionnaire (CCQ)[35] via telephone interview at
2 weeks. The CCQ is a patient-centred health status
measure that has been well validated and is widely
used in patients with COPD [36]
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Table 1 Primary and secondary objectives and outcome measures
Objectives Outcome measures Time point(s) of evaluation of this outcome
measure
Primary To determine whether the
addition of a CRP POCT
(with training on test use
and advice on interpretation)
to usual care for managing
AECOPD leads to a reduction
in antibiotic consumption for
AECOPD compared to usual
care alone
Antibiotic consumption (any consumption
of antibiotics for AECOPD vs. no
consumption of antibiotics for AECOPD)
First 4 weeks post randomisation
Primary To determine whether the
addition of a CRP POCT (with
training on test use and advice
on interpretation) to usual care
for managing AECOPD leads to
a reduction in antibiotic
consumption for AECOPD
without negatively impacting on
COPD health status compared to
usual care alone
Recovery in terms of COPD health status
as assessed using the Clinical COPD
Questionnaire (CCQ) total scores
2 weeks post randomisation
Secondary To assess the effect of using a
CRP POCT for AECOPD in primary
care on:
Prevalence of potentially pathogenic
bacteria (including S. pneumoniae,
Haemophilus spp. and Enterobacteriacae)
cultured from sputum at 4 weeks and the
proportion of bacteria that are resistant
4 weeks post-randomisation
Prevalence of commensal organisms
cultured from throat swabs at 4 weeks
and proportion of bacteria that are resistant
4 weeks post randomisation
COPD health status over time measured
using the CCQ total score
At weeks 1, 2 and 4 post randomisation
CCQ symptoms domain At weeks 1, 2 and 4 post randomisation
CCQ function state domain At weeks 1, 2 and 4 post randomisation
CCQ mental state domain At weeks 1, 2 and 4 post randomisation
Total antibiotic consumption (number of
days antibiotics consumed for AECOPD/any
reason)
First 4 weeks post randomisation
Health utility measured using the
EuroQol-5D (EQ-5D)
At weeks 1, 2 and 4 and at month 6 post
randomisation
All-cause antibiotic consumption During the first 4 weeks post randomisation
Antibiotic prescribing At the index consultation
Antibiotic prescribing During the first 4 weeks post randomisation
Use of other COPD treatments including
orally administered steroids
During the first 4 weeks post randomisation
Adverse effects potentially attributable to
antibiotics prescribed for the exacerbation
During the first 4 weeks post randomisation
Primary and secondary care consultations,
including hospitalisations
At week 4 and month 6
Costs (total NHS cost) and cost-effectiveness At month 6
Incidence of pneumonia (measured by
patient and GP report)
At week 4 and month 6
Disease-specific, health-related quality of
life over time measured using the CRQ-SAS
(dyspnoea, fatigue, emotion function, mastery
and total scores)
At month 6
AECOPD acute exacerbation of chronic obstructive pulmonary disease, CCQ Clinical COPD Questionnaire, CRP C-reactive protein point-of-care test, POCT point-of-care
test, CRQ-SAS Chronic Respiratory Disease Questionnaire, self-administered, standardised, GP general practitioner
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A 4-week time window was selected for the antibiotic
consumption outcome in order to measure the con-
sumption of antibiotics prescribed at the initial consult-
ation in addition to those that are related to the
AECOPD in question, but are initiated or prescribed at a
later date. The CCQ outcome is measured at 2 weeks as
this is the time when most patients will have recovered
and, therefore, the point at which a difference would be
most indicative of a delayed recovery.
Secondary outcome measures are listed in Table 1.
Setting and timing
The first winter period will comprise an internal pilot in
10–15 general practices in Wales (2014 to 2015). Follow-
ing the pilot, we aim to have at least 70 general practices
in the UK that are open to recruitment during the
winters of 2015-2016 and 2016-2017.
Trial intervention
PACE will assess the use of a CRP POCT to guide
antibiotic treatment decisions for patients presenting
in primary care with AECOPD. Patients randomised
to the intervention arm will have a CRP POCT at
every consultation for AECOPD that occurs in the 4
weeks following randomisation. Control patients will
not have a CRP POCT (as part of this study) at any
time during their participation.
The CRP POCT Afinion device (Alere Inc.) and CRP
cartridges will be offered to practices implementing the
study (http://www.alere.com/en/home/product-details/
afinion-crp.html). This POCT requires 1.5 μl of capillary
blood (finger prick) and takes less than 4 min to provide
a quantitative result. Other validated, CE-marked devices
and CRP cartridges giving a quantitative result within
the range of the Afinion POCT, and requiring a similar
volume of blood from a finger prick, will also be eligible
for use in the study where a practice prefers to use CRP
POCTs that they might already be using.
The prescribing clinician will use the results of the CRP
POCT to help guide their antibiotic prescribing decision
when consenting patients are randomised to care with the
addition of the CRP POCT. Participating clinicians (GPs,
practice nurses and health care assistants) will be provided
with study-specific training, which will include guidance,
for the clinical prescribers, on interpreting CRP results in
the context of AECOPD (Table 2).
Control arm
Patients randomised to the control arm will receive
usual clinical care. All participating sites will be provided
with information on current best practice.
Trial procedures
GP site selection and training
The study will be implemented in at least 70 general
practices from five regional centres in the UK using
existing National Institute for Health Research (NIHR)
and Health and Care Research Wales infrastructure,
supported by research professionals’ networks and a new
Primary Care Incentive Scheme (Wales).
The trial team will monitor recruitment and, if ne-
cessary, close some practices and/or expand to new
practices/regions.
All staff involved in trial-specific procedures (including
recruitment/consent, collection of trial data, application of
intervention and clinical assessments) will be appropri-
ately trained in the relevant aspects of the procedures and
in Good Clinical Practice (GCP) processes. This training
will include providing an overview of the aims and ration-
ale for the study, a summary of National Institute for
Health and Care Excellence (NICE) and The Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD)
Table 2 Guidance on interpreting C-reactive protein (CRP) results
CRP guidance:
The decision to prescribe antibiotics or not has to be based on a
comprehensive assessment of the likely risks and benefits given:
• The patient’s underlying health status (chronic obstructive
pulmonary disease (COPD) severity, comorbidities, frailty)
• Clinical features of the current exacerbation
Measurement of CRP can aid decision-making but is not meant to
replace clinical assessment.
Patients with the following features are likely to be at increased risk of
complications:
• Severe COPD (GOLD grade III)
• Past history of severe exacerbations (requiring hospitalisation)
• Significant comorbidities (e.g. heart failure, poorly controlled
diabetes, lung cancer)
Sputum purulence is currently the best clinical predictor of bacterial
infection. However:
• Patient-reported sputum colour is generally not reliable
• Purulence can be increased in viral infections as well as bacterial
infections
• Try and obtain a sputum sample in order to objectively assess
sputum purulence where possible
• Ask the patient how much the colour of their sputum has changed
from its usual colour. This is particularly pertinent when it is not
possible to objectively assess their sputum
CRP measurement:
CRP < 20 Antibiotics are unlikely to be beneficial and usually should
not be prescribed
CRP 20–40 Antibiotics may be beneficial – mainly if purulent sputum is
present. You may decide to prescribe antibiotics after taking
into account the patient’s underlying health status and the
features of the current exacerbation
CRP > 40 Antibiotics are likely to be beneficial. Consider prescribing
antibiotics unless the patient is assessed as being at lower
risk of complications and unlikely to have a bacterial
infection (no increased sputum purulence and no features
suggesting severe exacerbation)
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guidance on managing AECOPD, and training in
interpreting CRP POCT results (Table 2).
Representatives from Alere Inc. or the study team will
provide general practices (who will be using an Afinion
CRP machine) with specific training in using the CRP
POCT, including quality-control procedures.
Participant recruitment and consent
The recruitment process is summarised in Fig. 1.
Participating general practices will identify all potentially
eligible patients at the start of the study usually from
their existing COPD registers. Identified patients will
be sent a letter, from their general practice, informing
them about the study and a Participant Information
Sheet (PIS). The letter will include informing the
patient that if they are interested in taking part in the
study and if they have home ‘rescue packs’ which
contain antibiotics, that they should consider contact-
ing their surgery for a timely appointment before
deciding to start to taking their home supply of
antibiotics.
Fig. 1 Participant flow diagram
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Participants
Assessment of participant eligibility:
A GP or nurse responsible for managing the patient’s
current illness will complete the eligibility assessment.
Patients will be eligible for the trial if they meet the in-
clusion criteria and none of the exclusion criteria (Table 3).
Once consented to the study, participants will be allo-
cated a unique trial number (participant ID), which will
be the primary identifier for participants in the trial.
Randomisation
Participants will be remotely randomised, following con-
sent, using an online computerised randomisation system
created by the Centre for Trials Research at Cardiff Uni-
versity. This will be operational 24 h a day. In addition, an
8.30 a.m. to 6.30 p.m. telephone back up will be available
if the online system fails or the general practice has prob-
lems accessing the online site.
Participants will be randomised in a 1:1 ratio to receive
either usual care alone (control) or usual care with the
addition of CRP POCT (intervention). Randomisation will
use minimisation, with a random element set at 80%
to improve the integrity of the randomisation process.
Anthonisen criteria (categorised as type 1, 2 or 3) will
be used as a minimisation variable, so that balance is
achieved with respect to differing levels of COPD ex-
acerbation severity. Remote allocation will maintain
allocation concealment from both the participant and
the recruiting clinician up to the point of interven-
tion, as this is an open study.
Data collection
In order to facilitate the process of patient recruitment
and data collection into busy routine clinics, data collec-
tion can be conducted by any suitably trained clinician
(nurse, health care assistant or GP). The timing and type
of assessment (Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) Figure) is
described in Fig. 2.
A SPIRIT Checklist is included as an Additional file
(Additional file 1).
Baseline appointment
The clinician carrying out the baseline appointment will
record the number of days that the participant reports
having symptoms from the acute exacerbation, their med-
ical history, and clinical examination results (temperature,
pulse, oxygen saturation and whether tachypnoea,
crackles, wheezes, diminished vesicular sounds and evi-
dence of consolidation).
A sputum sample (when participants are able to pro-
duce sputum) and throat swab samples (using charcoal
swabs) will be obtained from the patient at the baseline
appointment and recorded on the baseline Case Report
Form (CRF). Recruiting clinicians will assess and record,
on the baseline CRF, the colour of the participant’s
sputum against a Bronkotest chart (Bronkotest Ltd.).
Participants will be asked to self-complete the baseline
CCQ and the baseline European Quality of Life-5 dimen-
sions (EQ-5D) questionnaire at this visit. The CRP test re-
sults will be recorded on the baseline CRF for those
randomised to care with the addition of the CRP POCT.
Antibiotic prescribing and other management deci-
sions will be recorded for all patients following random-
isation, and after CRP testing for those randomised to
the intervention.
Follow-up data collection
The trial team will aim to telephone all participants at 1
week and 2 weeks post randomisation to collect infor-
mation on their medication usage during that time
period and also to obtain their responses to questions on
the week-1 and week-2 CCQ and EQ-5D questionnaires.
Participants will be invited to return to the surgery for a
face-to-face consultation at 4 weeks post randomisation.
Table 3 Eligibility criteria
Inclusion criteria Exclusion criteria
Has a current acute exacerbation
(presenting with at least 1 of the
following: increased dyspnoea,
increased sputum volume,
increased sputum purulence) that
has lasted for at least 24 h and no
longer than 21 days
The responsible GP feels urgent
referral to hospital is necessary
Diagnosis of COPD in clinical
record/on COPD practice register
Severe illness (e.g. suspected
pneumonia, tachypnoea > 30
breaths/min, respiratory failure)
Age 40 years or more Concurrent infection at another
site (e.g. UTI, cellulitis) that is likely
to produce a systemic response
Able to provide informed consent Past history of respiratory failure
or mechanical ventilation
Patient should be able to provide
the primary outcome data at 2
and 4 weeks within the expected
windows
Currently taking antibiotics or has
taken antibiotics for this acute
exacerbation of COPD
Active inflammatory condition
(e.g. flare up of rheumatoid
arthritis, gout or polymyalgia
rheumatica)
Has cystic fibrosis, a current
tracheostomy or bronchiectasis
Immunocompromised (e.g. AIDS,
taking systemic immunosuppressive
therapy or receiving anti-cancer
radiotherapy or chemotherapy)
Currently pregnant
Previously been recruited into the
PACE study
COPD chronic obstructive pulmonary disease, GP general practitioner,
UTI urinary tract infection
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The Chronic Respiratory Disease Questionnaire, self-
administered, standardised (CRQ-SAS) and the EQ-5D
will be posted to participants for completion and return
at 6 months.
Telephone calls – week 1 (time window of −1/+2 working
days) and week 2 (time window of −1/+7 working days).
Participants will be contacted by telephone by a mem-
ber of the trial team. Participants will be given paper
versions of the week-1 and-week 2 CCQ and EQ-5D
questionnaires at their baseline visit and asked to
complete them on each appropriate day (day 8 and day
15, with the baseline appointment being on day 1) prior
to the telephone interview in order to facilitate data
collection.
Face-to-face visit – week 4 (time window of −3/+14
working days).
The week-4 face-to-face appointment will be arranged
at the time of baseline assessment and appointments will
be conducted by a member of the clinical team in the
general practice or a clinical study officer/research nurse
working for the local clinical research network at the
general practice. The following data will be captured:
medication consumption, adverse effects, time off paid
work, diagnosis of pneumonia since the baseline
appointment, any further CRP tests since the baseline
appointment, health care consultations. Sputum (where
possible) and throat swab samples will be obtained from
the participant and the colour of the sputum assessed
against a Bronkotest chart. Participants will be asked to
self-complete the week-4 CCQ and the week-4 EQ-5D
questionnaire at this visit. If a successful appointment
does not take place at week 4, the study team will con-
tact the participant by telephone to obtain a minimum
dataset. This dataset includes antibiotic consumption
during the third and fourth weeks after randomisation,
health care resource use and completion of the CCQ
and EQ-5D questionnaires. If the participant has missed
their week-1 or week-2 follow-up telephone call, the site
will be asked to carry out a minimum dataset with
the participant at the week-4 appointment. This data-
set captures information on the participants’ medica-
tion consumption.
Collection of relevant data from electronic medical
records at 6 months
Antibiotics prescribed in the 12 months prior to study
inclusion, spirometry results and a full blood count
result obtained prior to study inclusion will be recorded.
Spirometry results, prescriptions, and health service
utilisation data will be recorded for each participant for
the 6-month period following randomisation. General
practices will be asked to provide these data on a pro-
forma basis from a medical records review; alternatively,
the data will be collected by a member of the trial team
or clinical study officer/research nurse.
Fig. 2 Schedule of assessments (SPIRIT figure)
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Patient self-reported CRQ-SAS and EQ-5D – 6 months
Participants will be sent a copy of the CRQ-SAS and
EQ-5D at 6 months post randomisation by post. Partici-
pants will be telephoned by the trial team 1 week after
the due date to remind them to return the questionnaire
by post or to offer to complete these instruments over
the telephone at that point. If the questionnaire is not
received within 1 week of the first telephone reminder,
the trial team will telephone the participant again.
Adverse events
Hospitalisation is expected within this patient popula-
tion and will be collected and reported as part of routine
follow-up. All other events fulfilling the definition of a
serious adverse event (SAE), including death, that occur
between the time of consent and the 4-week follow-up
will be reported to the coordinating research centre
within 24 h of the site becoming aware of the event.
Microbiological assessment
Sputum (if available) and throat swab samples will be
obtained at the recruitment visit (baseline) and at the
face-to-face visit at week 4 and will be sent to the Spe-
cialist Antimicrobial Chemotherapy Unit (SACU), Public
Health Wales at the University Hospital of Wales. Not
all patients will be able to produce a sputum sample on
request and, therefore, we would expect to have a lower
return rate for these samples as compared to the throat
swab samples at both baseline and week 4.
Sputum sample appearance (including colour and
consistency) will be noted and all samples will be processed
using the laboratory’s standard operating procedures. Po-
tential pathogenic bacteria (including S. pneumoniae, Hae-
mophilus influenzae/parainfluenzae, Pseudomonas spp.,
Enterobacteriaceae and Staphylococcus aureus) found in
the sputum will be identified using the Matrix Assisted
Laser Desorption Ionising Time of Flight Mass Spectrom-
etry (MALDI-ToF-MS) and semiquantitative counts
recorded. Susceptibilities will be performed on relevant
bacterial species from sputum samples by disc diffusion
using European Committee on Antimicrobial Susceptibility
Testing (EUCAST) methodology and breakpoints. Throat
swabs (charcoal) will be added to Tryptone soya broth and
50 μL spiral plated onto a range of non-selective plates and
selective plates for identification purposes (e.g. Columbia
blood agar, Isosensitest with blood) and antimicrobial-
selective plates containing penicillin, third-generation
cephalosporins, doxycycline, levofloxacin and clarithromy-
cin at concentrations consistent with EUCAST break-
points). Total bacterial counts of commensal organisms
will be recorded on non-selective and selective agars; pro-
portional quantification of resistant isolates will be deter-
mined from the selective media. All pathogens recovered,
sputum samples and remaining broth from throat swabs
will be stored at −80 °C.
Process evaluation
A qualitative process evaluation will be embedded in the
trial to provide a better understanding of the implemen-
tation and receipt of the intervention and the context in
which it is delivered. This will aid interpretation of out-
come results and possible uptake of the intervention
should the trial have favourable benefits and risks [37].
Semistructured interviews will be carried out with up to
30 members of the participating primary care teams and
up to 30 patients to gather in-depth information on their
experience of participating in the study and their
thoughts of management of AECOPD in primary care.
These will be conducted by telephone. Approximately a
third of these interviews will take place during the pilot
phase of the trial, with the remainder being carried out
during the full trial.
The objectives of the qualitative process evaluation are
to:
1. Understand patient perspectives on the use of the
CRP POCT to help guide the management of
AECOPD
2. Understand clinician perspectives on the use of the
CRP POCT to help guide the management of
AECOPD
3. Understand barriers and facilitators to using the
CRP POCT in primary care and to inform possible
implementation and roll-out (if appropriate),
including:
(a)Views of primary care team members on
conducting POCT testing for AECOPD in
primary care
(b)Patient perspectives on the routine management
of AECOPD, including the use of antibiotics
(c)Primary care clinicians’ views on the challenges
involved in the routine management of AECOPD
An additional objective during the pilot phase will be
to examine perceptions of the research processes to
identify facilitators and barriers to participation so that
these can be addressed as far as possible prior to the full
trial phase.
Flexible topic guides will be used for the clinician and
patient interviews covering themes relating to these
objectives. The interviews will be audio-recorded and
will be approximately 30 min in duration.
Patients who have agreed to be contacted for an inter-
view will be telephoned by the research team within 2
weeks of their 4-week follow-up appointment with their
GP (i.e. 4–6 weeks from their initial consultation). The
trial team will write to participating practices to invite
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them to take part in the qualitative interviews, and this
will be followed up by a telephone call to arrange an
interview with a member of the primary care team.
Purposive sampling will be used to capture a range of
views from health professionals and patients. During the
internal pilot stage, approximately equal numbers of
patients in each trial arm will be sampled to assess the
acceptability of research procedures in each group. In
the full trial, only patients from the CRP POCT arm will
be interviewed. Patients will be sampled across geo-
graphical regions and will include patients who had, or
had not, been prescribed antibiotics at their initial con-
sultation. Similarly, general practices across all regions
will be sampled. Interviews will be conducted with pre-
scribing clinicians (i.e. GPs and nurse practitioners) and
non-prescribing members of the primary care team who
have been involved with the trial. In the internal pilot
phase of the trial, recruitment of the primary care team
will be associated with experience of the research pro-
cesses (e.g. recruitment of patients), while in the full trial
phase we will focus on members of the primary care
team with experience of carrying out and/or interpreting
results of the CRP POCT.
As part of a quantitative process evaluation, we will
estimate adherence to the allocated treatment arm based
on patient reports of receiving a finger-prick blood test
and, where possible, verify and supplement these data
from other sources, such as GP records and CSV files
stored on the CRP Afinion machine.
Analysis
Statistical considerations
Sample size
We aim to have sufficient power to detect a 15% reduc-
tion from an estimated 70% that consume antibiotics for
the AECOPD during the 4 weeks following randomisa-
tion [7]. Trials using CRP testing to reduce antibiotic
prescribing for lower respiratory tract infection have
resulted in absolute reductions in antibiotic prescribing
in the region of 13–22% [32, 38, 39]. Even relatively
small changes in prescribing are likely to have beneficial
effects on resistance at a population level [16]. Detecting
a difference in proportions between 0.70 and 0.55 at the
5% significance level and with 90% power requires a
total of 434 participants, inflated to 544 to account for
the loss to follow-up of approximately 20% of partici-
pants. In addition, we aim to have sufficient power to
demonstrate that participants managed with CRP POCT
are no worse (non-inferior), compared to those managed
without CRP POCT, in terms of their COPD health
status measured by the CCQ 2 weeks following random-
isation. Assuming an expected difference between groups
of zero, a non-inferiority margin of 0.3 lower than the low-
est minimal clinically important difference and a common
standard deviation of 1.1 [40], based on a one-sided sig-
nificance level of 0.05 and 90% power, we would need 462
participants, inflated to 580 to account for the loss to
follow-up of approximately 20% of participants.
Formulating our overall hypothesis using the Intersection-
Union Test [41] we will carry out our individual subhy-
pothesis tests at the 5% level and, if both are significant,
conclude overall significance at the 5% level. Power will
be affected by the level of correlation between the two
outcomes and their respective effect sizes. The impact
on overall power is at its greatest when there is zero
correlation between outcomes and effect sizes are iden-
tical (in this case, the overall power is the product of
the powers for testing each individual subhypothesis)
[42, 43], and decreases with increasing correlation of
outcomes and the more different effect sizes become.
We do not expect our effect sizes to be similar, as our
co-primary outcomes are two very different constructs
(i.e. not two patient-reported outcome measures that
are likely to yield similar effect sizes). We also antici-
pate that the outcomes will not be entirely independent
(in those participants who do in fact require antibiotics,
antibiotic consumption is likely to be related to COPD
health status). We will, therefore, aim to recruit at least
650 participants to maintain an overall power of
between 81 and 90%.
Statistical analysis
Participant characteristics and clinical measures will be
summarised using frequencies and percentages, means
and standard deviations, or medians and interquartile
ranges as appropriate. There will be no planned interim
analysis. The assessments made for the internal pilot will
be based on recruitment and follow-up rates with no
between-group comparison of outcomes. All analyses will
be presented as estimates of treatment effects (adjusted
mean differences or odds ratios, as appropriate), with as-
sociated 95% CIs and p values. The main trial analysis will
be based primarily on modified intention-to-treat (MITT)
population, which will include all randomised participants
who provide outcome data, regardless of protocol devia-
tions or intervention received. Missing outcome data will
be imputed using multiple imputation in order to obtain a
secondary analysis of the primary outcomes based on the
full intention-to-treat (ITT) population. A Complier Aver-
age Causal Effect (CACE) analysis, that takes into account
departures from randomised treatment while maintaining
a comparison of groups as randomised, will also be con-
ducted on the primary CCQ analysis [44]. The conclu-
sions drawn on the primary CCQ analysis will be based
on both the MITT and CACE analyses. (i.e. the upper
limit of the one-sided 95% CI will have to exclude 0.3 in
both analyses for non-inferiority to be concluded).
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All planned analyses will be described in detail in a
Statistical Analysis Plan (SAP), which will be finalised
prior to database lock.
Primary analysis
Our first primary analysis will compare the odds of con-
suming an antibiotic for an acute exacerbation during the
4 weeks following randomisation, in each trial arm, using
logistic regression. Our second primary analysis will com-
pare the mean CCQ score between each trial arm using
linear regression, with baseline CCQ scores included as a
covariate, and a one-sided 95% CI constructed to assess
non-inferiority. We will test if two-level models are re-
quired, due to clustering by practice, and fit a single level
model if it is not needed. Modelling assumptions will be
tested, with appropriate adjustments made in the presence
of any violations. Missing primary outcome data are likely
to be minimal, but will be accounted for in sensitivity ana-
lyses using multiple imputation, where we will assume
that primary outcome data are missing at random given
observed measurements.
Our second primary analysis, testing the non-inferiority
of management with CRP versus no CRP with respect to
the CCQ, will be based on our pre-specified margin of 0.3.
Should our observed difference be between 0.3 and 0.4
(0.4 is the minimal clinically important difference (MCID)
for the outcome), we will consider our results more fully,
reflecting on differences found in antibiotic consumption
and secondary outcomes (e.g. antibiotic resistance, EQ-5D
etc.) in the two trial arms.
Further secondary analyses of the primary outcomes
will be conducted:
1. To determine whether any changes in inclusion/
exclusion criteria following the internal pilot had any
impact on trial findings. The primary analyses will
be extended by including an explanatory variable
that indicates whether a participant was recruited
before or after the change in criteria. The interaction
between this variable and trial arm will be included
to assess any differential effect this change may have
had on the conclusions of the study
2. Modelling antibiotic consumption as repeated
observations within individuals using a generalised
linear mixed model
Subgroup
Differential intervention effects on the primary out-
comes will be assessed by fitting interaction terms in the
primary models between trial arm and the following:
 COPD severity (Gold grades I/II/III/IV), from most
recent spirometry assessment
 Severity of COPD exacerbation (Anthonisen criteria
type 1, 2 or 3)
 Presence of a potentially pathogenic bacteria
cultured from sputum sample at baseline
Two exploratory mediation analyses will be conducted
using causal modelling techniques to determine whether
the effect of the intervention on: (1) antibiotic prescrib-
ing and (2) COPD health status is mediated through
steroid prescribing.
Secondary analysis
Secondary outcomes will be analysed in a similar man-
ner to the primary outcomes, with linear, logistic, and
Poisson regression models fitted as appropriate.
Economic evaluation
A within-trial health economic analysis will be undertaken
from a health service perspective (UK NHS). Costs due to
patient absences from work will also be considered but
reported separately. The health economic evaluation
will include cost-effectiveness, cost-utility and cost-
consequences analyses. A trial-based budget impact
analysis will be undertaken to estimate the likely im-
pact of the use of CRP POCT in the management of
antibiotic prescribing for COPD on NHS budgets.
Prior to commencement of the analysis, a health eco-
nomic analysis plan will be produced and reviewed by
the trial team to be incorporated in the SAP.
Costs will include all resources used in the delivery of
CRP POCT. This includes staff training (including travel if
relevant), costs of CRP POCT kits and staff time required
within the general practices. Resource use through CRP
POCT implementation will be estimated through inter-
views with general practice staff, manufacturers and the
trial team. Where additional costs are required (e.g. re-
lated to the CRP POCT test), we will obtain them from
relevant sources, e.g. manufacturer list prices. Health care
resource use (e.g. antibiotic prescribing and consumption,
use of other COPD treatments including orally adminis-
tered steroids primary- and secondary-care consultations,
hospitalisations, adverse events) will be collected using
data from the in-trial CRFs, participant booklet, the 4-
week follow-up questionnaire and an adapted Client
Service Receipt Inventory (CSRI) integrated in the 6-
month note review to assess the change in profile of
health care use as a result of the intervention compared to
usual care. Costs will be assigned using published unit
costs (e.g. PSSRU, British National Formulary (BNF) and
NHS reference costs) where available and valued in £ ster-
ling. The health care costs in both the intervention and
the control arm will be summated with mean difference
per patient in costs (including 95% CIs) calculated for the
intervention compared to usual care. As the trial duration
Bates et al. Trials  (2017) 18:442 Page 11 of 15
is less than 12 months, discounting will not be applied to
costs or outcomes.
The primary co-outcomes (assessed at 4 weeks) will be
used in the cost-effectiveness analysis. Given that the aim
of the trial is whether CRP POCT-informed management
of patients with AECOPD can reduce antibiotic use with-
out negatively impacting on recovery, we will consider a
range of scenarios. A base-case analysis will report an in-
cremental cost-effectiveness ratio (ICER) presenting the
additional cost of producing an extra unit (%) reduction in
antibiotic prescribing (expressed as cost per unit % anti-
biotic prescription avoided). If the main trial fails to dem-
onstrate non-inferiority in terms of the CCQ (as defined
above) then the intervention would (if usual conditions
apply) likely be regarded as not cost-effective.
We will test a range of scenarios as part of the sensitivity
analysis, e.g. best case/worse case scenarios based on the
results of the co-primary outcomes to explore the impact
on the ICER. A threshold analysis will be undertaken to
assess the willingness to accept of the costs of obtaining a
reduction in antibiotic prescribing, should the CCQ score
fall between the values which will warrant further explor-
ation within the main trial analysis. In addition, we will
also explore possible scenarios to reflect subsequent adop-
tion in routine general practice, e.g. exclude the purchase
and running costs of the CRP POCT equipment to reflect
that the equipment may be used with general practices for
a variety of POCT interventions.
We will also undertake a within-trial cost-utility ana-
lysis (CUA) to assess the incremental costs per quality-
adjusted life year (QALY) gained as a result of the use of
CRP POCT compared to usual care at 6 months using
the EQ-5D to generate QALYs. QALYs incorporate
quantity of life (additional life years) and quality of life
in one measure. Thus, by dividing the difference in costs
by the difference in QALYs, cost per QALY can be calcu-
lated for each comparison.
Generally, the UK National Institute for Health and
Care Excellence (NICE) considers an intervention cost-
effective if one of the following applies.
 The intervention is less costly and more clinically
effective compared with all other relevant
alternatives. In this case, no ICER is calculated as
the strategy in question dominates the alternatives
 The intervention has an ICER of less than £20,000
per QALY compared to the next best alternative.
This means that an investment of up to £20,000 in
order to achieve an additional QALY is considered
cost-effective
The ICER resulting from the CUA will be compared
to the willingness-to-pay threshold of £20,000 per
QALY gained as standardised by NICE. No conditions
for non-inferiority will be applied in this analysis. Re-
sults will be reported as ICERs showing the extra cost
of producing one extra QALY or the extra savings
achieved by sacrificing one additional QALY.
For both analyses, deterministic sensitivity analysis will
be undertaken to assess the extent to which parameter
uncertainty affects the ICER. Probabilistic sensitivity
analyses will be run to estimate the probability of the
ICER falling below a range of willingness-to-pay (or
accept) thresholds as standardised by NICE. For the
cost-effectiveness analysis, no such threshold exists, thus
we will examine the academic literature and opinions
from the clinical team on what would constitute a suit-
able willingness to pay.
A cost-consequence analysis will present all relevant
primary and secondary outcomes alongside the costs in
tabular form (without combining them into ICERs) to
leave decision-makers the option to form their own view
of relative importance.
A trial-based budget impact analysis (BIA) will be
undertaken to estimate the likely impact of the use of CRP
POCT on NHS budgets through implementation costs,
changes in health care usage and potential reduction of
antimicrobial resistance. The BIA will be based on the size
and composition of the trial population and informed by
trial data supplemented by the best available published
evidence where required. Sensitivity analyses will be
undertaken to estimate the range of a potential budget
impact considering parameter uncertainty.
Qualitative evaluation
Interviews will be fully transcribed verbatim and checked
for accuracy. Data will be analysed using framework ana-
lysis. This is a systematic approach to a thematic qualitative
analysis that allows for easy comparisons between and
within cases, facilitates sharing and discussion of data, and
allows for clear linking/access from developed themes to
original data [45]. Framework analysis involves five stages:
(1) familiarisation with the data, (2) development of a the-
matic framework, (3) applying thematic codes to all of the
data (indexing), (4) retrieving and summarising coded data
in a chart and (5) interpreting the data by drawing infer-
ences and pulling together relevant themes. Framework
analysis is particularly useful when there are a number of
clear research aims that have guided the questions, while
allowing new themes to emerge from the data that are rele-
vant to the research question. Dual coding will be carried
out for 10% of the interviews to allow for an assessment of
coding validity. NVivo qualitative analysis software will be
used to assist coding.
Discussion
AECOPD lead to increased morbidity, emergency hos-
pital attendances, hospitalisations, health care costs, and
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more rapid disease progression and deterioration in
quality of life [46]. Most exacerbations are managed
without recourse to POCTs and most patients are pre-
scribed antibiotics, despite evidence that these prescrip-
tions do not always benefit them and may cause harm to
the individual patients and contribute to antimicrobial
resistance. POCT CRP testing may help clinicians better
target antibiotic prescribing, ensuring that antibiotics are
prescribed for those patients who benefit and other
interventions are targeted to those who will not.
POCTs have been widely promoted for improving the
care of patients who have acute infections [1]. Most evalu-
ations of diagnostic devices consider analytic performance
without evaluating impact on patient outcomes or costs.
However, new tests should not be introduced into routine
clinical care if they do not improve outcomes that matter
to patients individually or to society, including consider-
ation of impact on recovery and quality of life, antibiotic
prescribing and resistance [2–4].
The PACE study will be the first pragmatic, randomised
controlled, clinical trial to evaluate the clinical and cost-
effectiveness of the addition of CRP POCT to clinical as-
sessment for AECOPD in primary care. It will establish
whether a CRP POCT can safely and cost-effectively be
used to target antibiotic treatment for AECOPD so that
overall antibiotic prescribing and thus consumption is
decreased without compromising patients’ COPD health
status. If the results of the study are positive (i.e. signifi-
cant reduction in antibiotic prescribing with no evidence
of significant impairment in symptomatic recovery) then
implementation into practice is likely to be achieved
swiftly. NICE guidelines on pneumonia already recognise
a role for CRP POCT in deciding whether to prescribe an-
tibiotics, and the use of CRP POCT is increasing in the
UK. Potential barriers to uptake include the cost of test-
ing, training, quality control and integration with labora-
tory systems, connectivity with electronic medical records,
practitioner attitudes, and impact on clinical workflow.
However, these barriers have been successfully mitigated
in many European countries where CRP POCT use is
now widespread [47].
Trial status
At the time of manuscript submission, the status of this
study is that patient recruitment is ongoing.
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